Clinical Trials
49 trialsCisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Eastern Cooperative Oncology Group
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
MK-3475-048
Merck Sharp & Dohme LLC
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
ITACa
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
KEYNOTE-177
Merck Sharp & Dohme LLC
ELAN-UNFIT
Gustave Roussy, Cancer Campus, Grand Paris
BEACON CRC
Pfizer
CheckMate 651
Bristol-Myers Squibb
Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
Canadian Cancer Trials Group
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
Canadian Cancer Trials Group
MK-3475-040
Merck Sharp & Dohme LLC
Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma
Trans Tasman Radiation Oncology Group
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Bristol-Myers Squibb
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Amgen
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Radiation Therapy Oncology Group
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Radiation Therapy Oncology Group
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
Radiation Therapy Oncology Group
CHANGE2
Merck KGaA, Darmstadt, Germany
KESTREL
AstraZeneca
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
Bristol-Myers Squibb
Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery
Federation Francophone de Cancerologie Digestive
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
Swiss Cancer Institute
ARTSCANIII
Lund University Hospital
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
National Cancer Institute (NCI)
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
2007-01
Groupe Oncologie Radiotherapie Tete et Cou
Erbitux MEtastatic Colorectal Cancer Strategy Study
Catholic University of the Sacred Heart
TAILOR
Merck KGaA, Darmstadt, Germany
TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
US Oncology Research
PETACC-8 miR-31-3p and miR-31-5p Ancillary Study
IntegraGen SA
CRYSTAL
Merck KGaA, Darmstadt, Germany
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Eli Lilly and Company
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
SWOG Cancer Research Network
COMETS
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
CHANCE
Merck KGaA, Darmstadt, Germany
H&N07
Associazione Volontari Pazienti Oncologici
CHANGE
Merck KGaA, Darmstadt, Germany
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)
Merck KGaA, Darmstadt, Germany
EXPAND
Merck KGaA, Darmstadt, Germany
FLEX
Merck KGaA, Darmstadt, Germany
NEXT
Merck KGaA, Darmstadt, Germany
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Eli Lilly and Company
Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer
Dutch Colorectal Cancer Group
FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer
The Nordic Colorectal Cancer Biomodulation Group
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
Eli Lilly and Company
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
Eli Lilly and Company